Abstract
Severe pneumonia is a major challenge in the Intensive Care Unit, as it is characterized by high morbidity and mortality. A high rate of patients with pneumonia, in particular ventilator-associated poneumonia, develops septic shock. Although some interesting results have been reported in uncontrolled studies where IgM-enriched human intravenous immunoglobulins were added to the standard treatment of septic shock, a well-conducted clinical trial is missing[1]. Also, physiopathological data supporting such a trial are presently insufficient.
Highlights
Severe pneumonia is a major challenge in the Intensive Care Unit, as it is characterized by high morbidity and mortality
Some interesting results have been reported in uncontrolled studies where IgMenriched human intravenous immunoglobulins were added to the standard treatment of septic shock, a wellconducted clinical trial is missing [1]
We aimed to evaluate if Pentaglobin, a commercially available IgM-enriched polyclonal preparation, reduced pulmonary and systemic inflammation in an experimental model of Gram negative pneumonia causing septic shock
Summary
Severe pneumonia is a major challenge in the Intensive Care Unit, as it is characterized by high morbidity and mortality. A high rate of patients with pneumonia, in particular ventilator-associated poneumonia, develops septic shock. Some interesting results have been reported in uncontrolled studies where IgMenriched human intravenous immunoglobulins were added to the standard treatment of septic shock, a wellconducted clinical trial is missing [1]. Physiopathological data supporting such a trial are presently insufficient
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
